Basit öğe kaydını göster

dc.contributor.authorElli, M.
dc.contributor.authorDagdemir, A.
dc.contributor.authorBozkurt, C.
dc.contributor.authorPinarli, F. G.
dc.contributor.authorDuzgun, A.
dc.contributor.authorOzmen, Z. C.
dc.contributor.authorAcar, S.
dc.date.accessioned2020-06-21T14:28:33Z
dc.date.available2020-06-21T14:28:33Z
dc.date.issued2012
dc.identifier.issn0006-9248
dc.identifier.urihttps://doi.org/10.4149/BLL_2012_120
dc.identifier.urihttps://hdl.handle.net/20.500.12712/16763
dc.descriptionPinarli, Faruk Guclu/0000-0002-3241-2478en_US
dc.descriptionWOS: 000309197900004en_US
dc.descriptionPubMed: 22979908en_US
dc.description.abstractObjective: Osteopontin (OPN) is an adhesive glycoprotein that interacts with a variety of cell surface receptors, including several integrins and CD44. OPN is expressed and secreted by numerous human malignancies. CD44 play an important role in tumor growth and metastasis. We aimed to evaluate serum levels of osteopontin and CD44 in patients with lymphorethicular malignancies in childhood. Methods: We studied serum levels of CD44 and OPN levels of 54 patients (26, 18 and 10 patients with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and acute lymphoblastic leukemia (ALL), respectively) at the diagnosis. Results: The mean levels of OPN were significantly higher in patients (5.42 +/- 8.24 ng/ml) than in controls (3.89 +/- 1.96 ng/ml). The mean levels of CD44 levels were also significantly higher in patients (3.82 +/- 2.31 ng/ml) than in controls (1.96 +/- 0.62 ng/ml), and significantly higher in the advanced stages than in early stages. The mean levels of the CD44 in NHL, HL and ALL were 3.49 +/- 2.00, 3.56 +/- 1.74, and 5.15 +/- 3.50 respectively. Serum OPN and CD44 levels were found to be increased in parallel (p=0.003). A more advanced disease and/or poor prognostic factors were seen in 9 patients who had both serum CD44 and OPN levels higher than 2SD of the control. Conclusion: Elevated levels of both CD44 and OPN at the diagnosis may predict an unfavorable outcome in childhood leukemias and lymphomas (Tab. 2, Fig. 3, Ref. 44). Full Text in PDF www.elis.sk.en_US
dc.description.sponsorshipOndokuz Mayis UniversityOndokuz Mayis Universityen_US
dc.description.sponsorshipThis study was supported by Ondokuz Mayis University Research Fund.en_US
dc.language.isoengen_US
dc.publisherComenius Univen_US
dc.relation.isversionof10.4149/BLL_2012_120en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectosteopontinen_US
dc.subjectCD44en_US
dc.subjectlymphomaen_US
dc.subjectleukemiaen_US
dc.subjectchildrenen_US
dc.titleSerum osteopontin and CD44 levels in lymphoreticular malignancies in childrenen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume113en_US
dc.identifier.issue9en_US
dc.identifier.startpage534en_US
dc.identifier.endpage538en_US
dc.relation.journalBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster